Prior studies in CF murine models of P. aeruginosa infection effectively utilized IFN-γ as a systemic therapy [60], and patients with CGD inject IFN-γ subcutaneously to prevent infections with species including Burkholderia[34]. This evidence concerns the gene IFNG and chronic granulomatous disease.